查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1800891

2025 年至 2033 年青光眼治療市場報告（按藥物類別、適應症、最終用戶和地區分類）

Glaucoma Therapeutics Market Report by Drug Class, Indication, End User, and Region 2025-2033
出版日期: | 出版商: IMARC | 英文 143 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球青光眼治療市場規模達84億美元。展望未來， IMARC Group預計到2033年，該市場規模將達到141億美元，2025-2033年期間的複合年成長率（CAGR）為5.35%。北美目前佔據市場領先地位，這得益於其先進的醫療基礎設施、日益​​提升的認知度、尖端治療手段的可及性、強力的監管支持以及大量面臨青光眼風險的老齡人口。全球青光眼盛行率的不斷上升、早期診斷技術的不斷進步、眼科遠距醫療的日益普及以及外科手術領域的眾多技術創新，這些都是推動市場發展的一些因素。

青光眼是全球永久性失明的主要原因之一，每年確診的人數都在增加。此疾病通常進展緩慢且無症狀，這使得早期發現更加困難，導致需要持續治療的患者群體更大，從而拓寬了青光眼治療市場。此外，公眾意識的提升和青光眼相關教育的加強，正在促使更多人接受篩檢，從而實現更早的發現。早期介入導致治療需求增加，因為患者希望在視神經嚴重受損之前控制病情，從而支持市場成長。此外，製藥公司和醫療機構對研究計畫的投入不斷增加，也促使新療法的發現，包括專注於維護視神經健康的神經保護療法。這種對創新的重視帶來了更多的治療選擇，從而拓寬了市場供應，並為患者有效控制青光眼帶來了新的希望。

青光眼治療市場趨勢/促進因素：

外科手術的進步

外科技術的進步正在影響青光眼治療市場，尤其是微創青光眼手術 (MIGS) 的興起。 MIGS 為青光眼的治療帶來了革命性的變化，它提供了更安全的替代方案，相比傳統手術，併發症更少、恢復期更短、操作更簡單。這項進步為外科醫生提供了更多治療選擇，同時降低了患者的風險和不適感。此外，包括微支架和創新引流系統在內的手術器械的進步也正在提高青光眼手術的療效。一個重要的創新案例是愛爾康於2025年在美國推出的 Voyager™ DSLT，這是首款全自動直接選擇性雷射小樑整形術 (SLT) 設備。該設備無需使用角膜鏡或手動瞄準，即可提供120個雷射脈衝，從而簡化了 SLT 手術流程，提高了準確性並最大限度地降低了手術複雜性。這些技術創新增強了人們對外科手術的信任，促進了市場擴張並提高了治療效果。

學名藥的成長

學名藥青光眼藥物的日益普及，為更多患者提供了經濟有效的治療方案。前列腺素類似物等知名青光眼藥物的學名藥，在保持其有效性的同時，為品牌藥物提供了一種經濟實惠的替代品。這一趨勢對於提高治療可及性至關重要，尤其對於那些可能面臨財務困難或保險覆蓋受限的患者而言。學名藥有助於降低醫療費用，同時使更廣泛的患者群體能夠獲得有效的青光眼治療。隨著越來越多的製藥公司推出知名藥物的學名藥，競爭愈演愈烈，從而導致價格下降和市場准入的擴大。 2024年，美國Glenmark Pharmaceuticals Inc.推出了Travatan Z-Travoprost眼藥水0.004%的學名藥，用於治療青光眼和眼高壓。該產品與山德士的參考藥物生物等效，並擴展了Glenmark的眼科產品組合。截至 2024 年 9 月，Travatan Z 在美國的年銷售額達到 6,620 萬美元。

基因治療的進展

基因治療的最新進展為治療青光眼提供了新穎且富有創意的方法。科學家正在研究旨在解決青光眼根本原因的基因療法，例如保護視網膜神經節細胞和改善粒線體功能。這些療法涉及將特定基因導入眼部，旨在降低眼壓，同時保護視神經完整性並增強視覺相關細胞的整體功能。隨著基因療法在臨床試驗中的進展，它有望成為傳統療法的替代療法，並可能帶來持久的優勢和更少的副作用。這些先進療法的研發吸引了大量投資和關注，透過為患者提供更精準、更有效的青光眼控制選擇，推動了市場擴張。 2024年，都柏林聖三一學院的研究人員宣布了一種突破性的青光眼基因療法，該療法可以保護視網膜神經節細胞並增強粒線體功能。該療法使用腺相關病毒（AAV）遞送的eNdi1基因，在動物和人類模型中改善了視覺相關細胞的功能。成立了一家分拆公司 Vzarii Therapeutics，以推動其進入臨床試驗階段。

青光眼治療市場的成長動力：

老年人口不斷增加

全球老齡人口不斷成長，尤其是在已開發國家和快速發展的國家，導致青光眼病例大幅增加。世界衛生組織 (WHO) 估計，到 2030 年，全球每六人中就有一人年齡在 60 歲或以上，預計到 2050 年這一數字將加倍，達到 21 億。這種人口結構變化導致青光眼易感患者數量增加，對有效的診斷方法、替代治療方法和持續管理方案的需求日益成長。老年人更容易患青光眼等長期疾病，通常需要持續治療以避免視力受損。因此，老年人口的不斷成長推動了對新療法的需求，包括藥物和手術治療。這一趨勢鼓勵對研發投入，以製定滿足老年患者獨特需求的客製化療法，從而進一步促進市場成長。

提高認知和早期診斷

提高人們對青光眼的認知對於刺激青光眼治療市場擴張至關重要。健康運動、眼科護理組織的努力以及資訊的普及都有助於提高人們對青光眼的認知。隨著越來越多的人認知到早期發現的重要性，對常規眼科檢查的需求也在增加，尤其是在高風險族群中。早期診斷可以及時干預，降低不可逆視力喪失的風險，並確保更好的治療效果。 2024年，艾伯維印度公司和Sightsavers印度公司發起了一項為期15個月的活動，以提高人們對青光眼的認知，並專注於40歲及以上的人。該計劃包括篩檢營、線上推廣和教育項目，以鼓勵早期診斷和治療。這種向積極主動醫療保健的轉變導致對青光眼藥物、診斷工具和手術治療的需求增加。因此，更高的認知直接推動了青光眼療法的採用。

藥物輸送系統的進展

緩釋植入物、淚點塞和注射等創新技術正在改變青光眼的治療方式。這些創新系統比傳統的眼藥水俱有更持久的藥效，因為傳統的眼藥水需要定期使用，這常常導致患者依從性不足。例如，緩釋系統可以提供數週甚至數月的藥物，最大限度地減少每日給藥的必要性，並提高治療依從性。這不僅提高了患者的舒適度，還保證了均勻的治療效果，最終實現更卓越的眼壓管理。對增強藥物傳遞系統的高度重視，正在催化對更先進的青光眼療法的需求。 2024年，Ripple Therapeutics宣布與AbbVie合作開發RTC-620，這是一種完全可生物分解的緩釋前房植入物，用於降低青光眼患者的眼壓。 Ripple將負責臨床前開發，而AbbVie將領導臨床試驗和商業化。該植入物允許重複給藥，無需使用聚合物或賦形劑，從而降低發炎風險。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：全球青光眼治療市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第6章：市場區隔：依藥品類別

  • 前列腺素類似物
  • BETA受體阻斷劑
  • α腎上腺素激動劑
  • 碳酸酐酶抑制劑
  • 聯合用藥
  • 其他

第7章：市場區隔：依指標

  • 開角型青光眼
  • 閉角型青光眼
  • 其他

第8章：市場區隔：按最終用戶

  • 醫院
  • 眼科診所
  • 門診手術中心
  • 其他

第9章：市場細分：依地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章：SWOT分析

第 11 章：價值鏈分析

第 12 章：波特五力分析

第13章：價格分析

第 14 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Aerie Pharmaceuticals Inc.
    • Allergan Plc
    • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
    • Inotek Pharmaceuticals Corp.
    • Merck & Co. Inc.
    • Novartis AG
    • Pfizer Inc.
    • Santen Pharmaceutical Co. Ltd.
    • SIFI SpA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2770

The global glaucoma therapeutics market size reached USD 8.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 14.1 Billion by 2033, exhibiting a growth rate (CAGR) of 5.35% during 2025-2033. North America currently leads the market because of advanced healthcare infrastructure, increasing awareness, access to cutting-edge treatments, strong regulatory support, and a large aging population at risk for glaucoma. The growing prevalence of glaucoma across the globe, continual advancements in diagnostic technologies for early detection, the rising adoption of telemedicine in ophthalmology, and numerous technological innovations in surgical procedures represent some of the factors that are propelling the market.

Glaucoma ranks among the top causes of permanent blindness globally, with a growing number of individuals being diagnosed annually. The condition typically advances gradually and asymptomatically, complicating early detection and resulting in a larger group of patients needing continuous therapeutic care, thereby broadening the market for glaucoma treatments. Moreover, increasing public awareness initiatives and better education regarding glaucoma are motivating more individuals to undergo screenings, resulting in earlier detections. Earlier intervention leads to an increase in the need for therapeutic treatments as patients aim to control the disease prior to substantial optic nerve damage, supporting the market growth. Besides this, heightened funding from pharmaceutical firms and healthcare institutions in research operations is leading to the identification of new therapies, including neuroprotective treatments focused on maintaining optic nerve health. This emphasis on innovation leads to additional treatment choices, thereby broadening the market offerings and providing patients with renewed optimism for effectively managing glaucoma.

Glaucoma Therapeutics Market Trends/Drivers:

Advancements in Surgical Procedures

Advancements in surgical technology are influencing the glaucoma therapeutics market, especially with the emergence of minimally invasive glaucoma surgeries (MIGS). MIGS is revolutionizing the treatment of glaucoma by providing safer alternatives with reduced complications, quicker recovery periods, and simpler procedures in contrast to conventional surgeries. This advancement provides surgeons with additional treatment options while reducing risks and discomfort for patients. Moreover, developments in surgical instruments, including micro-stents and innovative drainage systems, are improving the effectiveness of glaucoma surgeries. A significant instance of innovation is the 2025 introduction of Alcon's Voyager(TM) DSLT in the US, the initial fully automated Direct Selective Laser Trabeculoplasty apparatus. This instrument streamlines the SLT process by providing 120 laser pulses without requiring a gonio lens or manual targeting, enhancing accuracy and minimizing procedural intricacy. These technological innovations enhance trust in surgical procedures, boosting market expansion and enhancing treatment results.

Growth of Generic Drugs

The increasing availability of generic glaucoma drugs is providing more access to cost-effective therapies. Generic forms of well-known glaucoma medications, like prostaglandin analogs, offer an economical substitute to name-brand treatments while maintaining their effectiveness. This trend is essential for increasing access to treatment, especially for patients who might face financial limitations or restrictions in insurance coverage. Generic medications contribute to lower healthcare expenses while allowing a wider patient demographic to gain access to effective treatments for glaucoma. With the rise of pharmaceutical companies launching generic versions of well-known medications, competition intensifies, leading to lower prices and broader market access. In 2024, Glenmark Pharmaceuticals Inc., USA launched a generic version of Travatan Z-Travoprost ophthalmic solution 0.004%-for treating glaucoma and ocular hypertension. The product is bioequivalent to Sandoz's reference drug and expands Glenmark's ophthalmic portfolio. Travatan Z recorded $66.2 million in annual U.S. sales as of September 2024.

Advancements in Gene Therapy

Recent advancements in gene therapy are providing novel, creative methods for addressing the condition. Scientists are investigating gene therapies aimed at addressing the root causes of glaucoma, such as the protection of retinal ganglion cells and the improvement of mitochondrial functions. These treatments, which involve introducing particular genes to the eye, seek to reduce intraocular pressure while also protecting optic nerve integrity and enhancing the overall function of vision-related cells. With the advancement of gene therapy in clinical trials, it emerges as a hopeful substitute for conventional treatments and may provide lasting advantages with reduced side effects. The creation of these advanced treatments is drawing considerable investment and focus, driving market expansion by offering patients more precise, efficient choices for controlling glaucoma. In 2024, Trinity College Dublin researchers announced a breakthrough gene therapy for glaucoma that protects retinal ganglion cells and enhances mitochondrial function. The therapy, using an AAV-delivered eNdi1 gene, improved vision-related cell performance in animal and human models. A spinout, Vzarii Therapeutics, was formed to advance it toward clinical trials.

Glaucoma Therapeutics Market Growth Drivers:

Growing Geriatric Population

The increasing elderly population worldwide, especially in advanced and swiftly developing nations, is leading to a significant rise in glaucoma cases. The World Health Organization (WHO) estimates that by 2030, one in every six individuals globally will be 60 years or older, a figure anticipated to double by 2050, hitting 2.1 billion. This demographic change is expanding the number of patients vulnerable to glaucoma, leading to a growing need for effective diagnostic methods, treatment alternatives, and continuous management approaches. Senior individuals are more vulnerable to long-term ailments such as glaucoma, which frequently necessitates ongoing treatment to avert vision impairment. Therefore, the rising number of elderly individuals is driving the demand for new treatments, including both medical and surgical options. This trend is encouraging investment in research operations to formulate customized therapies that meet the unique requirements of elderly patients, further bolstering the market growth.

Rising Awareness and Early Diagnosis

Raising awareness regarding glaucoma is crucial for stimulating the expansion of the glaucoma therapeutics market. Health campaigns, efforts by eye-care organizations, and greater information accessibility are all helping to raise awareness about the condition. With an increasing number of people recognizing the significance of early detection, there is a rise in the demand for routine eye examinations, especially among high-risk groups. Early diagnosis allows for timely intervention, reducing the risk of irreversible vision loss and ensuring better treatment outcomes. In 2024, AbbVie India and Sightsavers India initiated a 15-month campaign to raise awareness about glaucoma, focusing on people aged 40 and older. The initiative featured screening camps, online outreach, and educational programs to encourage early diagnosis and treatment. This shift towards proactive healthcare leads to higher demand for glaucoma medications, diagnostic tools, and surgical treatments. As a result, greater awareness is directly driving the adoption of glaucoma therapies.

Advancements in Drug Delivery Systems

Innovations, such as sustained-release implants, punctal plugs, and injectable formulations, are changing how glaucoma treatments are delivered. These innovative systems offer a more enduring effect than conventional eye drops, which necessitate regular application, frequently resulting in insufficient patient adherence. Sustained-release systems, for instance, can provide medication for weeks or even months, minimizing the necessity for daily administration and enhancing treatment compliance. This not only improves patient comfort but also guarantees uniform therapeutic outcomes, ultimately resulting in superior management of intraocular pressure. The heightened emphasis on enhancing drug delivery systems is catalyzing the demand for more sophisticated glaucoma therapies. In 2024, Ripple Therapeutics announced a collaboration with AbbVie to develop RTC-620, a fully biodegradable sustained-release intracameral implant for reducing intraocular pressure in glaucoma. Ripple will handle preclinical development, while AbbVie will lead clinical trials and commercialization. The implant allowed repeat dosing without polymers or excipients, reducing inflammation risk.

Glaucoma Therapeutics Industry Segmentation:

Breakup by Drug Class:

  • Prostaglandin Analogs
  • Beta Blockers
  • Alpha Adrenergic Agonists
  • Carbonic Anhydrase Inhibitors
  • Combination Drugs
  • Others

Prostaglandin analogs represents the largest market segment

The prostaglandin analogs segment in the market is predominantly driven by their efficacy in reducing intraocular pressure with fewer systemic side effects compared to other classes of glaucoma medications. The once-daily dosing convenience of these drugs also contributes to patient compliance, thereby increasing its market demand. Innovation in formulations and delivery mechanisms is another major factor contributing to its market share. Intellectual property expiry and subsequent entry of generics, however, pose a challenge to market growth. Lastly, their versatile compatibility with other classes of glaucoma medications makes them a preferred choice in combination therapies, bolstering the segment's prominence.

On the other hand, the beta blockers, alpha adrenergic agonists, carbonic anhydrase inhibitors, combination drugs and other segments are influenced by a diverse range of factors such as affordability, varied mechanisms of action, and well-established safety profiles. These drugs are often prescribed in cases where Prostaglandin Analogs are contraindicated or not effective. Despite their efficacy, the need for multiple daily dosing can impact patient compliance. Availability of generics in this category also makes it a cost-effective option for treatment.

Breakup by Indication:

  • Open Angle Glaucoma
  • Angle Closure Glaucoma
  • Others

Open angle glaucoma represents the largest market segment

The open-angle glaucoma segment is primarily fueled by its prevalence, constituting the majority of glaucoma cases globally. Increased awareness and advancements in diagnostic techniques have led to earlier and more frequent detection of this condition. The availability of multiple treatment options, ranging from medications to surgeries, offers a comprehensive approach to managing open-angle glaucoma. Aging demographics further amplify the incidence rates, thereby driving glaucoma therapeutics market demand. Government initiatives aimed at eye health contribute to the overall market growth for this segment.

On the other hand, the growth in angle closure glaucoma and other segments is primarily driven by an aging population, as the condition is more prevalent among older adults. Advances in diagnostic technologies have also contributed to the segment's expansion by enabling earlier and more accurate detection of the condition. In addition, the increased awareness about the severity of untreated angle-closure glaucoma, which can lead to blindness, has led to higher demand for effective treatments.

Breakup by End User:

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgery Centers
  • Others

Hospitals accounts for the majority of the market share

Hospitals are major consumers in the glaucoma therapeutics market, given their capability to offer advanced diagnostic and surgical interventions. The consolidation of healthcare facilities and investment in state-of-the-art ophthalmic departments contribute to the segment's growth. Additionally, hospitals are often the first point of contact for emergency eye conditions, thereby positioning them as crucial stakeholders. Public and private insurance coverages also incentivize treatment in hospital settings, increasing patient throughput and consumption of glaucoma medications.

On the other hand, the growth in ophthalmic clinics, ambulatory surgery centers, and other segments can be attributed to the specialized focus on eye care, the availability of advanced diagnostic equipment, and faster patient turnover. Increasing consumer preference for specialized care is also a contributing factor. Decentralization of healthcare services and the expansion of ambulatory surgery centers make these settings accessible for minor procedures and regular check-ups. The growth is further supported by flexible payment options and shorter waiting times.

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

North America exhibits a clear dominance, accounting for the largest glaucoma therapeutics market share

The glaucoma therapeutics market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

The market in the North America region is significantly impelled by high healthcare expenditure, robust insurance frameworks, and the presence of leading pharmaceutical companies are primary drivers. Furthermore, the region is home to a diverse and aging population, thereby creating a natural demand for glaucoma treatments. Technological advancements in drug formulation and delivery, backed by substantial investments in research and development, also fuel glaucoma therapeutics market growth.

Regulatory support in terms of expedited approvals and grants fosters innovation, providing a favorable environment for market expansion. Government initiatives in healthcare education and eye screenings contribute to early diagnosis and, in turn, drive demand for therapeutics. Accessibility to specialty ophthalmic clinics and ambulatory surgery centers adds another layer of convenience, encouraging timely intervention.

The availability of both branded and generic drugs offers options across various price points, catering to a wide consumer base. Furthermore, collaborations between public and private sectors in healthcare initiatives serve to increase awareness as well as facilitate entry and acceptance of novel therapeutic solutions in the market.

Competitive Landscape:

The major players in the market are persistently working to develop more effective and less invasive treatment options. They are investing heavily in clinical trials to produce medicines and devices that provide longer-lasting relief with fewer side effects. Collaborations with research institutions and healthcare organizations are common strategies these key players are adopting. Market leaders are also expanding their portfolios by launching innovative products specifically designed to manage different types of glaucoma. Furthermore, these companies are working diligently to meet stringent regulatory requirements, ensuring that their products are both safe and effective. Furthermore, they are also focusing on patient education and awareness programs as a part of their market expansion strategies, thereby offering a favorable glaucoma therapeutics market outlook.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

  • Aerie Pharmaceuticals Inc.
  • Allergan Plc
  • Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
  • Inotek Pharmaceuticals Corp.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Santen Pharmaceutical Co. Ltd.
  • SIFI S.p.A
  • Teva Pharmaceutical Industries Ltd

Key Questions Answered in This Report

  • 1.How big is the global glaucoma therapeutics market?
  • 2.What is the expected growth rate of the global glaucoma therapeutics market during 2025-2033?
  • 3.What are the key factors driving the global glaucoma therapeutics market?
  • 4.What has been the impact of COVID-19 on the global glaucoma therapeutics market?
  • 5.What is the breakup of the global glaucoma therapeutics market based on the drug class?
  • 6.What is the breakup of the global glaucoma therapeutics market based on the indication?
  • 7.What is the breakup of the global glaucoma therapeutics market based on the end user?
  • 8.What are the key regions in the global glaucoma therapeutics market?
  • 9.Who are the key players/companies in the global glaucoma therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Glaucoma Therapeutics Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Prostaglandin Analogs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Beta Blockers
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Alpha Adrenergic Agonists
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Carbonic Anhydrase Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Combination Drugs
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Others
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast

7 Market Breakup by Indication

  • 7.1 Open Angle Glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Angle Closure Glaucoma
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Ophthalmic Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Ambulatory Surgery Centers
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Aerie Pharmaceuticals Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
    • 14.3.2 Allergan Plc
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Bausch & Lomb Incorporated (Bausch Health Companies Inc.)
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 SWOT Analysis
    • 14.3.4 Inotek Pharmaceuticals Corp.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Merck & Co. Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Novartis AG
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Pfizer Inc.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Santen Pharmaceutical Co. Ltd.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 SIFI S.p.A
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Glaucoma Therapeutics Market: Major Drivers and Challenges
  • Figure 2: Global: Glaucoma Therapeutics Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Glaucoma Therapeutics Market: Breakup by Drug Class (in %), 2024
  • Figure 4: Global: Glaucoma Therapeutics Market: Breakup by Indication (in %), 2024
  • Figure 5: Global: Glaucoma Therapeutics Market: Breakup by End User (in %), 2024
  • Figure 6: Global: Glaucoma Therapeutics Market: Breakup by Region (in %), 2024
  • Figure 7: Global: Glaucoma Therapeutics Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 8: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Glaucoma Therapeutics (Prostaglandin Analogs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Glaucoma Therapeutics (Beta Blockers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Glaucoma Therapeutics (Beta Blockers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Glaucoma Therapeutics (Alpha Adrenergic Agonists) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Glaucoma Therapeutics (Carbonic Anhydrase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Glaucoma Therapeutics (Combination Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Glaucoma Therapeutics (Combination Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Glaucoma Therapeutics (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Glaucoma Therapeutics (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Glaucoma Therapeutics (Open Angle Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Glaucoma Therapeutics (Angle Closure Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Glaucoma Therapeutics (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Glaucoma Therapeutics (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Glaucoma Therapeutics (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Glaucoma Therapeutics (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Glaucoma Therapeutics (Ophthalmic Clinics) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Glaucoma Therapeutics (Ambulatory Surgery Centers) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Glaucoma Therapeutics (Other End Users) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Glaucoma Therapeutics (Other End Users) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: North America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: North America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: United States: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: United States: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Canada: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Canada: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Asia Pacific: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Asia Pacific: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: China: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: China: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Japan: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Japan: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: India: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: India: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: South Korea: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: South Korea: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Australia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Australia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Indonesia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Indonesia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Europe: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Europe: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Germany: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Germany: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: France: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: France: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: United Kingdom: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: United Kingdom: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: Italy: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: Italy: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: Spain: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: Spain: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Russia: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Russia: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Latin America: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Latin America: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Brazil: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Brazil: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Mexico: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Mexico: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: Others: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: Others: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: Middle East and Africa: Glaucoma Therapeutics Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: Middle East and Africa: Glaucoma Therapeutics Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Global: Glaucoma Therapeutics Industry: SWOT Analysis
  • Figure 83: Global: Glaucoma Therapeutics Industry: Value Chain Analysis
  • Figure 84: Global: Glaucoma Therapeutics Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Glaucoma Therapeutics Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Glaucoma Therapeutics Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 3: Global: Glaucoma Therapeutics Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 4: Global: Glaucoma Therapeutics Market Forecast: Breakup by End User (in Million USD), 2025-2033
  • Table 5: Global: Glaucoma Therapeutics Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 6: Global: Glaucoma Therapeutics Market: Competitive Structure
  • Table 7: Global: Glaucoma Therapeutics Market: Key Players